More on REGN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $832.41 |
|
|||
| Open | $832.41 | ||||
| 52 Wk High | $592.36 | ||||
| 52 Wk Low | $325.35 | ||||
| Day High | $836.92 | ||||
| Day Low | $831.42 | ||||
| P/E | 219.65 | ||||
| EPS | $3.81 | ||||
| Volume | 91,133 | ||||
- Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
- Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
- Regeneron (REGN) Completes Acquisition of Decibel Therapeutics
- Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
- AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
- AbCellera (ABCL) Expands Multi-Target Antibody Discovery Collaboration with Regeneron (REGN)
- AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
- WestPark Capital Starts Regeneron Pharma (REGN) at Hold
- Form 4 REGENERON PHARMACEUTICAL For: Sep 08 Filed by: Schenkein David P
- Form 4 REGENERON PHARMACEUTICAL For: Sep 08 Filed by: Guarini Kathryn
Entities mentioned with REGN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Definitive Agreement | View Related Stories »
- Morgan Stanley | View Related Stories »
- PDUFA | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
